Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function

Inclusion Criteria: * Male and female participants 18 years and older. * Known or suspected focal liver lesions based on medical history and previous laboratory and/or imaging examinations. * Severe renal impairment (estimated glomerular filtration rate \[eGFR\] \< 30 mL/min/1.73 m\^2) based on medical history and previous laboratory examinations, at least once, within the last 3 months prior to the Baseline Visit, or participants with an increase in serum creatinine ≥ 0.3 mg/dL within 48 hours or ≥ 50% within 7 days prior to the Baseline Visit. Exclusion Criteria: * Participants with simple liver cysts only. * Any investigational drug or device within 6 weeks prior to the Baseline Visit. * Any magnetic resonance imaging (MRI) contrast media within 6 weeks prior to Baseline Visit or scheduled to receive any contrast medium before the last study visit. * Participants with severe hepatic impairment (according to Child-Pugh score C). * Participants scheduled for surgery before last study visit. * Participants with encephalopathy / neurodegenerative or acute neurological disorders. * Participants with hemochromatosis.